Artificial Axon Labs

Artificial Axon Labs is a biotechnology company developing a transformational drug discovery platform for neurodegenerative diseases, with an initial focus on Multiple Sclerosis (MS). The company's proprietary technology uses 3D-printed 'artificial axons'—synthetic fibers that mimic the mechanical and geometrical properties of human axons—to screen for drugs that promote remyelination. By combining these mimics with patient-derived human cells, the platform provides a more predictive, high-throughput environment for identifying first-in-class remyelinating therapies compared to traditional 2D cultures or animal models. The technology was originally developed at MIT and has been validated through collaborations with major pharmaceutical partners like Sanofi.